Fengyuan Pharma Gets Nod to Register Two Dialysis Solutions

Chinese drug regulator National Medical Products Administration granted drug registration certificates to two of Anhui Fengyuan Pharmaceutical's (SHE:000153) dialysis solutions, the company said in it

MT NewswiresMay 13 04:32 ET

Fengyuan Pharmaceutical (000153.SZ) obtained two drug registration certificates

Fengyuan Pharmaceutical (000153.SZ) announced that the company received approval from the State Drug Administration for low calcium peritoneal penetration...

Zhitong FinanceMay 10 05:24 ET

Fengyuan Pharmaceutical (000153.SZ): Low calcium peritoneal dialysis solution (lactate-G 1.5%) and low calcium peritoneal dialysis solution (lactate-G 2.5%) obtained drug registration certificates

Gelonghui, May 10, 丨 Fengyuan Pharmaceutical (000153.SZ) announced that recently, the company received the “Drug Registration Certificate” (certificate number: 2024S00742) for the low-calcium peritoneal dialysate (lactate-G 2.5%) and the “Drug Registration Certificate” (certificate number: 2024S00741) and low-calcium peritoneal dialysis solution (lactate-G 1.5%) approved and issued by the State Drug Administration.

Gelonghui FinanceMay 10 05:21 ET

Fengyuan Pharmaceutical (000153.SZ): The company currently has no traditional Chinese medicine cultivation base

Gelonghui May 9 丨 Fengyuan Pharmaceutical (000153.SZ) said on the investor interactive platform that the company currently has no traditional Chinese medicine cultivation base.

Gelonghui FinanceMay 9 03:19 ET

Anhui Fengyuan Pharmaceutical's (SZSE:000153) Problems Go Beyond Weak Profit

Anhui Fengyuan Pharmaceutical Co., Ltd.'s (SZSE:000153) stock showed strength, with investors undeterred by its weak earnings report. While shareholders may be willing to overlook soft profit numbers

Simply Wall StMay 7 18:13 ET

Fengyuan Pharmaceutical (000153.SZ): Net profit of 47.0109 million yuan in the first quarter increased 2.14% year over year

On April 25, Ge Longhui Pharmaceutical (000153.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,121 billion yuan, down 7.08% year on year; net profit attributable to shareholders of listed companies was 47.0109 million yuan, up 2.14% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 41.6746 million yuan, up 4.96% year on year; basic earnings per share were 0.1,416 yuan.

Gelonghui FinanceApr 25 09:27 ET